• Br-DAPI: What the Product Record Supports

  2026-10-14

  The APExBIO product description presents Br-DAPI as a DAPI fluorescent dye that binds A/T-rich regions in double-stranded DNA and becomes substantially more fluorescent on binding. That mechanism supports a conceptual role in DNA-associated fluorescence measurements, including supplier-described live and fixed cell staining, but no identity-matched study or independent performance data are available here.

• WTAP–GLS Splicing and Ferroptosis in HCC

  2026-10-14

  The supplied study proposes that EGFR–AKT signaling promotes a WTAP-dependent GLS isoform switch that supports glutamine use, antioxidant production, ferroptosis resistance, and hepatocellular carcinoma progression. Its multi-level design strengthens the mechanistic model, but the evidence remains bounded by incomplete reporting, model dependence, and correlational human data. Dehydroabietic acid is a separate supplier-described dual PPAR-α/γ agonist; the study provides no evidence that it affects this WTAP–GLS pathway.

• What the Fabp4 CRISPRi Study Shows—and Does Not

  2026-10-13

  A 2019 mouse study reported that adipocyte-targeted CRISPR interference against Fabp4 was associated with improvements in obesity-related phenotypes. The supplied evidence does not show that Dehydroabietic acid was used in that study or that its supplier-described dual PPAR-α/γ activity reproduces the reported gene-regulation effects. The findings remain preclinical and have important evidentiary and applicability limits.

• Canagliflozin and Renal Mitochondrial Remodeling

  2026-10-13

  A preclinical study in hypertensive–diabetic mice links Canagliflozin exposure with improved proximal-tubule mitochondrial structure and bioenergetics, while emphasizing sex-specific responses and limits on translation beyond the animal model.

• Thapsigargin in Context: Stress-Pathway Evidence

  2026-10-12

  Thapsigargin is a SERCA pump inhibitor commonly used to interrogate calcium signaling and endoplasmic reticulum stress, whereas the supplied 2024 Autophagy study examined metabolic and lysosomal stress through an AMPK–SQSTM1/p62–NRF2 feedback system. The study offers mechanistic insight but does not establish that thapsigargin reproduces this pathway or that findings from cellular and cancer models translate directly to clinical disease.

• VX-765 in Context: IL-1β Processing Study

  2026-10-12

  A source-grounded overview of a bioRxiv preprint examining how inflammatory caspases recognize and process IL-1β and IL-18, with clarification of what the findings do—and do not—establish about VX-765 and VRT-043198.

• CHIR 99021 Trihydrochloride: Evidence and Limits

  2026-10-10

  A source-grounded overview of CHIR 99021 trihydrochloride as a GSK-3 inhibitor, explaining its mechanistic rationale, the relevance of human intestinal organoid research, evidence quality, interpretation, and important limits for insulin signaling, stem cell, and glucose metabolism studies.

• Protein A/G Magnetic Beads: Product Overview

  2026-10-09

  APExBIO’s Protein A/G Magnetic Beads (SKU K1305) are described as recombinant Protein A and Protein G beads for Fc-region IgG capture and related affinity workflows. No matched research paper was available, so performance, selectivity, and application-specific outcomes cannot be independently assessed.

• Exendin-4 in Type 2 Diabetes Research

  2026-10-09

  Exendin-4, also called Exenatide, is a GLP-1 receptor agonist studied in beta-cell biology, glucose regulation, and recombinant production. Current evidence supports a mechanistic research role and a yeast-expression proof of concept, but does not establish therapeutic equivalence, oral delivery, manufacturing feasibility, or clinical benefit from the 2024 study.

• Octanoic Acid, PPARγ, and Macrophage Balance in IBD

  2026-10-08

  A 2025 Food Science & Nutrition study links octanoic acid-rich enteral nutrition with improved inflammatory bowel disease phenotypes through coordinated PPARγ, STAT-1, and STAT-6 signaling. Its mouse and cell-based evidence supports a mechanistic model of macrophage-polarization control, while the absence of clinical data limits direct translation to patient care.

• Tiamulin (Thiamutilin): Evidence Overview

  2026-10-08

  Tiamulin, also called Thiamutilin in the supplied product dossier, is a pleuromutilin antibiotic used mainly in veterinary medicine. Evidence supports a 50S-ribosome mechanism, while anti-inflammatory and cross-species applications remain more context-dependent and require careful interpretation.

• Estradiol, ERα, and T Cells After Hemorrhagic Shock

  2026-10-07

  The 2021 Scientific Reports study links estradiol-mediated immune recovery after hemorrhagic shock to ERα- and GPR30-associated suppression of endoplasmic reticulum stress. Its pharmacological comparison of estrogen-receptor ligands and stress modulators provides a mechanistic framework, while the animal-model design limits direct translation to human trauma care or breast cancer biology.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-07

  A 2025 GeroScience study introduces a genetically drug-sensitized yeast platform that substantially improves detection of TOR pathway inhibitors compared with a wild-type background. The system identified pathway-linked activity for established inhibitors and aminophylline, while finding no evidence of TOR inhibition for canagliflozin in this model, an important boundary for interpreting results in glucose metabolism research.

• PPARγ, Macrophage Polarization, and DSS-Induced IBD

  2026-10-06

  A 2025 study links PPARγ activation with reduced M1-like macrophage signaling, enhanced M2-associated markers, and improved disease features in a DSS-induced inflammatory bowel disease model. Its central contribution is a mechanistic framework connecting macrophage polarization to reciprocal STAT-1 and STAT-6 signaling, while its preclinical design limits direct conclusions about human IBD or other PPARγ-related disease areas.

• Dorsomorphin 2HCl: Reading AMPK Evidence

  2026-10-06

  Dorsomorphin 2HCl is an AMPK inhibitor that can help test whether AMPK contributes to metabolic phenotypes. This evidence-focused guide explains how to interpret its use in the 2025 LP.P101 mouse study while accounting for BMP signaling, hepcidin biology, and pharmacological limitations.

8718 records 1/582 page Next 12345 下5页 Last page